Abstract BALB/c mice were immunised with high or low density native human cartilage proteoglycans, or the respective core proteins obtained from chondroitin ABC lyase digestion. Mice injected with high density native proteoglycans developed arthritis whereas mice injected with low density proteoglycans or with core proteins did not.
Analysis of the immune response by enzyme linked immunosorbent assay (ELISA) and western blot showed a stronger and more polyspecific. response in animals injected with low density proteoglycans compared with mice with arthritis which had been injected with high density proteoglycans. Autoantibodies to mouse high density proteoglycans were only present in mice injected with native human high density proteoglycans, however. The data suggest that an arthritogenic epitope lies within the glycosaminoglycan rich region nf thp nat;vP nrntPnolvean mn1l-uIn wh;Ph Whalen, Robert L Karvonen, of antibodies to proteoglycans which cross react with native mouse proteoglycan. In the work reported here we have elaborated on this observation by exploring the arthritogenic potential of native low density proteoglycans and high density proteoglycans, and their respective core proteins. We found that although low density proteoglycans induced a higher immune response than high density proteoglycans, only the mice injected with native high density proteoglycans developed polyarthritis. The induction of arthritis in BALB/c mice appears to be related to the specificity of the autoimmune response to high density proteoglycans induced by native human cartilage proteoglycans.
Methods and materials

MICE
Inbred female BALB/c mice (five to seven weeks old) were obtained from Jackson T 2hnrntnrv (Rir H4nrhAr MA TT.CA) and wurn under associative conditions at 105 000 g for 70 hours at 10°C (Beckman Ultracentrifuge Model L5-75, 5OTi rotor). The density gradient was then fractionated into five equal volumes and the lower three fifths (A1A2A3) containing high density proteoglycans and the upper two fifths (A4A5) containing the low density proteoglycans were collected and separated from the gel at the top of the gradient. Additional buffer (0-4 M guanidine-HCl 50 mM sodium acetate, pH [5] [6] [7] [8] and solid caesium chloride to a density of g/ml for the fraction containing high density proteoglycans and 1 46 g/ml for the fraction containing low density proteoglycans were added and the two fractions were centrifuged again under the same conditions to obtain the lower three fifths (AlA2A3-AlA2A3) of the gradient containing the high density proteoglycans and the middle two fifths (A4A5-A2A3) containing the low density proteoglycans. The proteoglycan fractions were extensively dialysed against water at 4°C, lyophilised, and stored at -70°C. Neither proteoglycan fraction contained any hydroxyproline when analysed spectrophotometrically. ' 3 Proteoglycan fractions were analysed by sodium dodecylsulphate polyacrylamide gel electrophoresis as described by Laemmli,'4 stained with silver nitrate,'5 and then with toluidine blue 0 (Allied Chemical) in 0 1 M acetic acid.
PROTEOGLYCAN CORE PROTEINS
Core protein fractions of low and high density proteoglycans from fetal cartilage were prepared by enzyme digestion.'6 Proteoglycan (0-17 mg) was digested with one unit of purified chondroitin ABC lyase (ICN ImmunoBiologicals, Lisle, IL, USA) at 37°C for 25 hours in 100 mM Tris-HCI, 30 mM sodium acetate buffer (pH 8'0) containing 0-6 mg/ml bovine serum albumin as a stabiliser, 10 mM EDTA, 10 mM N-ethylmaleimide, 5 mM phenylmethylsulphonyl fluoride, and 0'36 mM pepstatin. After digestion, the fractions containing low and high density proteoglycans and a control (with lyase but without proteoglycans) were dialysed against 1 The strips were washed three times with PBS/ 0-3% Tween for five minutes at 5 ml/track and then washed once with just PBS for five minutes at S ml/track. The strips were placed in S ml/track of the secondary antibody solution (39-0 ml PBS, 10 g milk, 1 ml normal goat serum, 0-08 ml goat antimouse IgG conjugated to alkaline phosphatase (Fisher Scientific) at room temperature overnight. They were again washed three times with PBS/0-3% Tween for five minutes at S ml/track and once with PBS for five minutes at 5 ml/track. The strips were placed into the aqueous substrate solution (0-2 mg/ml nitroblue tetrazolium, 100 mM TRIS-HC1, pH 9*7, 0-5 mM magnesium chloride, 0-001 mM zinc chloride, 0-2 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (US Biochemicals), clinical signs of arthritis in mice and the temporal evolution of the disease. Eight out of 10 mice injected with high density proteoglycans had arthritis whereas none of the mice injected with low density proteoglycans or Freund's complete adjuvant alone developed the disease. This difference was highly significant (p<0001). Arthritis developed between the sixth and the fourteenth week after injection of the high density proteoglycans. Three arthritic mice progressed from redness and swelling (clinical score 1) to deformities (clinical score 2) in the affected limbs but no mice developed joint ankylosis. The disease in two mice was seen to enter remission with the clinical appearance of the affected limbs returning to normal after five days.
The histological assessment showed an aggressive joint disease in BALB/c mice immunised with high density proteoglycans. Extensive synovial proliferation, pannus formation, and erosive changes were present at the end of the study, and invasion of the articular cartilage by proliferative pannus at the joint margins was a consistent finding (fig 3) .
In the second experiment, mice injected with core protein from either high or low density proteoglycans, or native low density proteoglycans did not develop arthritis (0/6, all groups). All animals injected with native high density proteoglycans in this experiment developed arthritis (6/6).
ANTIBODY RESPONSE TO PROTEOGLYCANS Figure 4 shows the total serum antibody response to native low and high density proteo Figure 6 shows the electrophoretic and western blot analysis results. Bands in tracks 9 and 10 from the electrophoresis are the silver stained low and high density proteoglycan core protein fractions respectively, corresponding to different molecular weights within the core protein fractions digested by chondroitin ABC lyase. Bovine serum albumin (band Bi) with a molecular weight of 67 kilodaltons and migrating at the position of the lower arrow, and bovine serum albumin dimer (band B2) with a molecular weight of about 134 kilodaltons and migrating at the position of the upper arrow, were not injected into the mice, and provide a specificity control for the blot. Core proteins of low and high density proteoglycans in tracks 1 and 2 respectively were treated with pooled serum samples from the Freund's complete adjuvant control mice. There were no bands present on either track, indicating no antibodies to low or high density proteoglycan core proteins in mice injected with Freund's complete adjuvant. Likewise no binding activity was detected in the track with only chondroitin ABC lyase and bovine serum albumin for serum samples either injected with low or high density proteoglycans (fig 5, tracks 3 and 6 respectively) .
The binding activity of serum samples from mice injected with native low or high density proteoglycans against the core protein of high density proteoglycans (fig 6 41 In conclusion, our observations indicate that although BALB/c mice immunised with native molecule or core proteins from high and low density proteoglycans develop humoral and cellular immune responses, only mice injected with native high density proteoglycans develop autoantibodies to murine proteoglycan and arthritis. Further work on the molecular target of the arthritogenic response and the possible contribution of the response to proteoglycans induced by Freund's complete adjuvant is underway in this novel experimental model of arthritis. 
